VCP and frontotemporal dementia: To further test whether the beneficial effects of this approach may have therapeutic relevance for human ALS/FTD, we next examined the effects of treatment with arimoclomol in human models of ALS/FTD by establishing patient-derived cellular models of mutant VCP.